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Summary 
Counterregulatory effects following administration 
o f biosynthetic human proinsulin (BHPI) and human 
insulin (BHI) were compared during hypoglycemia 
standardized by means o f a glucose controlled insulin 
infusion system (GCIIS). 
Presented in part at the 19th Annual Meeting of the Euro-
pean Society for Clinical Investigation, Toulouse, France, 
April 24-27 , 1985. 
A total o f 0 .148±0 .010 U/kg o f BHPI had to be 
given by the GCIIS in order to obtain a minimal 
blood glucose (BG) o f 26±2 mg/dl ( x±SEM) at 43±2 
min . In contrast, 0 .083±0 .004 U/kg o f B H I were 
sufficient to produce a minimal BG o f 21±1 mg/dl 
(n.s.) at 35±1 min. (Ρ < 0.005). Moreover, BHPI 
infusion resulted in prolonged hypoglycemia and 
delayed blood glucose recovery. On a molar basis, 
the acute BG lowering effect o f BHPI was about 
13% that of B H I (BHPI 3 .94±0 .27 vs. B H I 0 .51±0 .03 
nmol/kg) . Serum proinsulin after BHPI reached its 
C u n i l u i fd t iv t ' S tudy uf Hurmufw i l C o u n t e n tMjul. j l iui ι D u r i n g ( iC I IS -Gu ided H y p o g l y c e m i a Josts 
maximum of 19.4i2 pmol/ml at 20 min. and still 
exceeded basal values markedly at t h e end of the 
t e s t period at 240 min. Serum insulin peaked at 10 
min. ( 162±48 μ υ / m l ) and had already returned to 
b a s a l values (7 .5± 1 μΐ ΐ /ml) alter 45 min. No s e v e r e 
side effects were observed and t h e r e was no need for 
glucose administration, but clinical symptoms of h y p o ­
glycemia were m o r e pronounced after BHPI. Com­
pared to B H I , BHPI produced a higher C o r t i s o l p e a k 
(252±16 vs. 168± 10 ng/ml), a m o r e pronounced 
secretion o f A C T H and GH as well as a stronger de­
cline of serum potassium (3 .20±0 .06 vs. 3 .58±0.08 
mmol/1). Counterregulatory prolactin secretion did 
not differ significantly. Urinary epinephrine s e c r e ­
t i o n following hypoglycemia after BHPI e x c e e d e d 
that after BHI (10 .3±4 .8 vs. 3.0±0.5 ng/120 min.) . 
Serum lactate increase after BHPI was m o r e prolonged 
(1 .68±0 .24 vs. 0.3710.14 mmol/1 at 120 min.) . 
BHPI-induced inhibit ion of lipolysis, as determined 
by free f a t t y a c i d patterns, was delayed and less 
pronounced. 
Our results indicate that the observed m o r e distinct 
glucose counterrcgulation is due to prolonged h y p o ­
glycemia rather t h a n to any specific BHPI action on 
t h e hypothalamic-pituitary axis. We regard t h i s as a 
consequence of the prolonged circulating and b i o ­
logical half-life. A preferential proinsulin action on 
the liver may play an additional role. Whether this 
"depot effect" may be beneficial in the treatment of 
diabetes mellitus remains to be established. 
Key-Words: Human Proinsulin, Recombinant DNA 
Technology, Glucose Counterrcgulation, Glucose 
Controlled Insulin Infusion System 
Introduction 
Recently, large amounts of human proinsulin have 
become available by recombinant D N A technology 
(Frank, Pettee, Zimmerman and Burck 1981), there­
by facilitating extensive metabolic in vitro and in 
vivo studies. 
Investigations carried out in healthy volunteers up 
to now, have shown distinct differences in hormone 
effects between human proinsulin and insulin. 
Apart from its relatively weak biological activity, 
human proinsulin is more potent in suppressing 
hepatic glucose production than in stimulating periph­
eral glucose disposal (Revers, Henry, Schmeiser, K o l ­
terman, Cohen, Bergenstal, Polonsky, Jaspan, Ruben­
stein, Frank, Galloway and Olefsky 1984). In addi­
t ion , the deactivation o f the in vivo actions o f pro­
insulin is markedly prolonged and, as a striking fea­
ture, the recovery of hepatic glucose production fol­
lowing cessation o f proinsulin infusion is dispropor­
tionately delayed (Glauber, Revers, Henry, Schmeiser, 
Wallace, Kol terman, Cohen, Rubenstein, Galloway, 
Frank and Olefsky 1986). These findings may be 
partially explained by pharmacokinetic factors such 
as circulating half-life (Glauber et al. 1986) meta­
bolic clearance rate (Revers et al. 1984), distribution 
volume and compartmentali/ation (Bottermann, 
Gray, Zilker, Heinzel, Frmler, Wahl and Lebender 
1985). Furthermore, differences in the cellular ac­
tions of proinsulin and insulin may play a role. 
The prolonged blood glucose-lowering effect of pro­
insulin as well as its preferential sustained action on 
the liver could be of therapeutic benefit in the treat­
ment o f diabetes mellitus (Bergenstal, Cohen, Lever, 
Polonsky, Jaspan, Blix, Revers, Olefsky, Kolter­
man, Steiner, Charrington, Frank, Galloway and 
Rubenstein 1984). 
Keeping this potential therapeutic use in mind, we 
decided to compare the counterregulatory effects 
following the administration o f either biosynthetic 
human proinsulin (BHPI) or human insulin (BHI) 
during hypoglycemia tests guided by a glucose con­
trolled insulin infusion system (GCIIS). In addi­
t ion, myocardial contractility was determined during 
hypoglycemia noninvasively. 
Materials and Methods 
Subjects 
8 healthy volunteers (3 female, 5 male; 25.311.0 
years; 63.413.0 kg (meanlSEM), taking no medica­
tions, were studied. Fach subject underwent 2 hypo­
glycemia tests: one wi th human proinsulin and one 
wi th human insulin. The study was approved by the 
ethic committee o f the Medical University Lübeck. 
A l l subjects gave wri t ten informed consent. 
Materials 
Biosynthetic human proinsulin (BHPI) was pre-
pared and characterized as previously described 
(Frank et al. 1981) and was supplied by El i Li l ly and 
Company, Indianapolis, Indiana/USA (CT-5765-2C). 
Biosynthetic human insulin (Biohumaninsulin normal) 
was provided by El i L i l ly and Company, Bad Hom-
burg/FRG. 
Glucose Controlled Insulin Infusion System (GCIIS) 
The details o f the GCIIS (Biosta tor®, Life Science 
Instruments, Miles Laboratories, Elkhart, Indiana/ 
USA) have been described elsewhere (Pfeiffer, Thum 
and Clemens 1974; Fogt, Dodd, Jenning and Clemens 
1978; Clemens, Chang and Myers 1978). The Bio-
stator GCIIS was used on static control. The follow-
ing constants were chosen: B I 35, QI 10, R I 20, 
F I 300 (Müller-Esch, Ball, Heidbüchel, Wood and 
Scriba 1984). 
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Fig. 1 Blood glucose (BG) 
and infusion rates (Rl) of bio-
synthetic human proinsulin 
(BHPI) and biosynthetic 
human insulin (BHI) during 
GCIIS-guided hypoglycemia 
tests in a healthy volunteer. 
The total dosage adminis­
tered is 0.143 U/kg for 
BHPI and 0.082 U/kg for 
BHI . 
2ώ0 Im m) 
Experimental Protocol 
After an overnight fast and bed rest, the subjects 
were connected to the GCIIS between 8 a.m. and 
9 a.m. Feedback controlled infusion of Bi lPI or 
BUI was discontinued and the device was only used 
for blood glucose monitoring when blood glucose 
had fallen by 40% of baseline values and initial 
clinical symptoms of hypoglycemia occurred (Fig. 1). 
Venous blood samples were drawn at - 1 0 , ±0 , +10, 
+20, +30, +45, +60, +90, +120, +150 and +240 min . , 
respectively, from an indwelling catheter placed in an 
antecubital vein. In addition, urine was collected 
during four 120 min . periods before, during and 
after hypoglycemia tests. 
Analytical Methods 
Serum A C T H ( INC; Stillwater, Minnesota/USA), 
Cortisol (Clinical Assays; München /Germany) , GH 
(Sorin, Hamburg/Germany), prolactin (Becton-
Dickinson; Heidelberg/Germany), insulin (Sorin; 
Hamburg/Germany) and C-peptide (Mall inkrodt; 
Dietzenbach/Germany) were determined by commer-
cially available radioimmunoassays. 
Serum proinsulin measurements were carried out by 
Eli L i l ly and Company, using a recently developed 
specific radioimmunoassay (Cohen, Nakabayashi, 
Bl ix , Rue, Shoelson, Root, Frank, Revers and Ruben-
stein 1985). 
Urinary epinephrine was determined by HPLC wi th 
electrochemical detection (Kraas, Schutt and Knuppen 
1982). 
Free fatty acids ( F F A ) were measured by HPLC 
(Ikeda, Shimada and Sakaguchi 1983). 
Serum potassium was determined by flame photo-
metry, serum lactate en/.ymatically. 
Systolic Time Intervals 
In 6 volunteers, systolic time intervals (PI:Ρ = pro-
ejection period; L V E T = left ventricular ejection 
time; QS2 = electromechanical systole and Q = PEP 
divided by L V E T (Weissler, Harris and Schoenfeld 
1969) were continuously monitored before the hypo­
glycemia tests, immediately after stopping feedback 
controlled proinsulin or insulin infusion and at 150 
min . ( A V L Myocard Check 970; Schaffhausen/ 
Switzerland). 
Statistical Methods 
Results are expressed as mean±SEM. Wilcoxon's 
test for paired differences and analysis o f variance 
for repeated measures over time (Winer 1971) were 
used. 
Results 
Figures 2—6 and Tables 1-4 show the results ob­
tained w i t h BHPI and B H I . The curves were achieved 
by calculating the mean±SEM at identical points o f 
time, whereas Table 1 gives the mean±SEM o f the in­
dividual peak or nadir levels, which differed slightly 
in time from the overall means. 
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Γ ig. 2 Blood glucose levels during GCIIS-guided hypo­
glycemia tests wi th BHPI (o o) and BHI ( · · ) in 
8 healthy volunteers (x±SEM). The corresponding pro­
insulin serum levels (o o) during BHPI-infusion and 
serum insulin levels ( · · ) during BHI-infusion on a 
logarithmic scale are also shown. 
A total o f 0 .148±0 .010 U/kg o f BHPI had to be 
given by the GCIIS in order to obtain a minimal 
blood glucose o f 26±2 mg/dl at 4 3 ± 2 min. (Tables 
2 - 3 ) . In contrast, 0 .083±0 .004 U/kg o f B H I 
(P < 0.001) were sufficient to produce a minimal 
blood glucose o f 21±1 mg/dl (n.s.) at 35±1 min . 
(Ρ < 0.005). Feedback controlled insulin infusion 
was stopped after 18±4 min . , whereas proinsulin 
infusion was discontinued after 29±5 min . (Ρ < 
0.001). 
BHI administration resulted in prolonged hypogly­
cemia and delayed blood glucose recovery as com­
pared to B H I (Fig. 2) . Accordingly, the calculated 
area under the blood glucose curve (AUC) was sig­
nificantly lower for BHPI than for B H I (BHPI: 
12.209±776 vs. B H I : 16 .350±326 mg/dl -min . ; 
Ρ < 0.01). 
On a molar basis, the blood glucose lowering effect 
o f BHPI was about 13% that o f B H I (BHPI 3 .94±0.27 
vs. BHI 0.51 ±0.03 nmol/kg) . 
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Fig. 3 Serum levels for ACTH and Cortisol during GCIIS-
guided hypoglycemia tests wi th BHPI {o o) and BHI 
( · · ) in 8 healthy volunteers (x±SEM). 
No severe side effects were observed and there was no 
need for glucose administration, but clinical symp­
toms of hypoglycemia were more pronounced after 
BHPI infusion. 
The basal serum proinsulin level was 0 .02±0.01 pmol/ 
m l ; during BHPI-infusion, a maximum of 19.4±2 
pmol /ml was reached after 20 min . (Fig. 2). A t the 
end o f the test period (240 min.) serum proinsulin 
levels still exceeded basal values markedly. In con­
trast, serum insulin peaked w i t h 162±48 μ υ / m l at 
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Fig. 4 Serum levels for GH and prolactin during GCIIS-
guided hypoglycemia tests wi th BHPI (ο- ο) and BHI 
( · · ) in 8 healthy volunteers (x±SEM). 
Fig. 5 Serum potassium and lactate during GCIIS-guided 
hypoglycemia tests wi th BHPI (o o) and BHI ( · · ) 
in 8 healthy volunteers (x±SEM). 
10 m i n . and had already returned to basal values 
(7 .5±1 μ ϋ / m l ) after 45 min . 
When comparing serum proinsulin and insulin levels 
on a molar basis, serum proinsulin concentration re­
quired for the induction o f hypoglycemia exceeded 
that o f insulin 20-fold. 
Mean basal C-peptide levels before proinsulin and 
insulin infusion were identical (1.1 ±0.1 Mg/l). B H I -
induced C-peptide inhibit ion reached its maximum 
between 45 and 90 min . (0.41 ±0.07 jug/l). 
Due to the known cross-reactivity between C-peptide 
and proinsulin in the C-peptide assay used, C-pep­
tide serum levels during proinsulin infusion could 
not be determined. This problem would have been 
overcome by a preceeding proinsulin extraction 
(Revers et al. 1984) or by using a specific C-peptide 
assay (Hampton, Beyzavi and Marks 1985); how­
ever, both methods were not available. 
Compared to B H I , hormonal counterregulation after 
BHPI was characterized by delayed and partially more 
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SYSTOLIC TIME INTERVALS 
HEART RATE [l/min] 
8 ° 1 rfl ° ' Ί * h r h 
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BHPI • BHI before during after hypoglycemia 
Fig. 6 Systolic time intervals during 
GCIIS-guided hypoglycemia tests wi th 
BHPI ( • ) and BHI ( • } in 6 healthy 
volunteers (x±SEM). PEP = preejection 
period, LVET = left ventricular ejection 
t ime, Q = PEP/LVET. 
Table 1 
in 8 hoa 
Feedback-controlled infused BHPI and BHI (U/kg) 
thy volunteers. 
BHPI 
0.207 
0.150 
0.151 
0.163 
0.134 
0.143 
0.108 
0.129 
BHI 
0.085 
0.101 
0.090 
0.090 
0.070 
0.082 
0.071 
0.078 
x±SEM 0.148±0.010 0.083±0.004 P<0.001 
Lactate maxima after BHPI and BHI were comparable, 
but the peak after BHPI occurred later (BHPI 113±21 
vs. BHI 48±5 min.) and lactate levels did not reach 
basal values at the end of the test period (Fig. 5). 
Table 4 shows the free fatty acid patterns during the 
hypoglycemia tests wi th BHPI and BHI . Proinsulin-
induccd inhibition of lipolysis was delayed and clear­
ly less pronounced. 
BHPI and B H I led to a comparable reversible decrease 
of the systolic time intervals PEP, L V E T , QS2 and Q 
during hypoglycemia; the transient heart rate increase 
was identical (Fig. 6) . 
distinct max imum hormone responses as well as by 
prolonged recovery. 
As can be seen from Figures 3 - 4 , prolonged secre­
tion o f A C T H , Cortisol and BG corresponded well 
w i th prolonged hypoglycemia; the higher Cortisol 
maximum is statistically significant (Table 2). 
Due to the large standard deviation in a limited num­
ber o f subjects, statistically significant differences 
in prolactin secretion could not be detected, although 
there was a tendency towards higher prolactin levels 
after BHPI infusion (Table 3) . 
Urinary epinephrine excretion after BHPI during the 
third collection period (120—240 min. ) exceeded 
that after B H I 3-fold (BHPI 10 .3±4.8 vs. BHI 3.0±0.5 
Mg/120 min . ; Ρ < 0.05). 
BHPI infusion resulted in a more distinct delayed 
hypokalemia w i t h prolonged recovery (Fig. 5). 
Discussion 
The aim o f this study was to compare the counter­
regulatory effects following administration o f BHPI 
and BHI during GCIIS-guided hypoglycemia tests. 
Using the GCIIS w i t h appropriate constants on static 
control (Müller-Esch et al. 1984), blood glucose 
nadirs obtained by feedback controlled BHPI and 
B H I infusion did not differ significantly. The total 
BHPI dosage administered exceeded that o f B H I 
approximately 1.8-fold (0.148 vs. 0.083 U/kg) . 
On a molar basis, a nearly 8-fold higher dosage o f 
BHPI had to be given (3.94 vs. 0.51 nmol/kg). This 
calculation is based on the assumption, that the bio-
logical potency, determined by rabbit hypoglycemia 
test, o f BHPI is 4 U/mg (Clinical Investigation Manual 
1984) and that o f B H I 28 U/mg. 
I f one defines biological potency as the quotient o f 
blood glucose decrease (mg/dl) and applied hormone 
Table 2 Mean basal values (bas.) and maximum (max.) or min imum (min.) levels obtained during GCIIS-guided hypoglycemia tests wi th BHPI and BHI for blood glucose (BG) .GH, 
A C T H , Cortisol, prolactin, potassium, lactate and free fat ty acids (FFA) in 8 healthy volunteers (x iSEM) . *P < 0.05; * *P < 0 .01 . 
BG (mg/dl) GH (ng/ml) ACTH (pg/ml) Cortisol (ng/ml) Prolactin (μυ/ml) Potassium (mmol/ l) Lactate (mmol/I) FFA (μιηοΙ/Ι) 
bas. min. bas. max. bas. max. bas. max. bas, max. bas. min. bas. min. bas. min. 
BHPI 79±8 26+2 1.9±1.2 39±8 23.5±3.0 250±42 100±10 241±14* 213±14 1212±470 4.35±0.18 3.20±0.06** 0.45±0.17 2.1 ±0.2 664±110 326±41* 
BHI 78±2 21 ±1 0.9±0.3 32±5 18.5±3.5 198±45 88± 9 168±10 223±15 482± 98 4.32±0.11 3.58±0.08 0.24±0.08 1.7±0.3 552±104 216±32 
Table 3 Individual serum prolactin levels (μυ/ml) during GCIIS-guided hypoglycemia tests wi th BHPI and BHI in 8 healthy volunteers. x±SEM is also shown. 
BHPI 
-10 ±0 10 20 30 45 60 90 120 150 240 min 
1 199 214 225 264 241 285 3500 3500 3500 2960 1300 
2 301 292 281 293 281 273 314 352 377 361 274 
3 275 225 195 237 180 176 1090 3202 2464 1104 503 
4 193 219 217 216 190 600 805 761 624 369 277 
5 192 190 183 198 244 192 312 354 303 250 186 
6 208 217 254 229 202 209 599 470 300 230 173 
7 166 195 186 254 228 227 246 429 320 340 227 
8 198 152 162 181 198 222 429 341 253 230 100 
x±SEM 217±16 213±14 213±14 234±13 221±12 273±48 912±383 1180±477 1018±442 731±334 3 7 4 H 3 9 
BHI 
1 258 248 197 202 176 233 238 198 176 174 224 
2 280 268 322 290 280 276 351 432 340 355 282 
3 185 195 149 215 233 360 302 246 203 176 117 
4 198 204 260 149 297 685 897 600 417 252 220 
5 178 198 208 231 224 274 275 258 216 196 162 
6 217 241 240 226 215 857 918 574 336 277 185 
7 296 279 290 275 236 495 437 394 338 215 140 
8 191 151 146 182 185 212 237 220 168 166 153 
x±SEM 225±16 223±15 227±22 221±16 231 ±15 424±83 4 5 7 H 0 1 365±57 274±33 226±30 185±19 
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dosage (nniol/kg) (Jones, Dron, l i l i is , Sonksen and 
Brandenburg 1986), BHPI has only a potency of 
13% compared to BHI . 
I f an identical dosage (U/kg) o f BHPI and B H I , as 
applied during hypoglycemia tests by bolus injec­
t ion , would result in identical blood glucose nadirs, 
the total molar BHPI dosage would exceed that o f 
B H I 4-fold. In this case, the biological potency of 
BHPI would be 23% that o f B H I . 
It is known, that the biological potency of insulin 
preparations determined by insulin hypoglycemia 
tests may vary up to 50% (Galloway, Spradlin, 
Root and Fineberg 1981; Home, Shepherd, Noy, 
Massi-Benedetti, Hanning, Burrin and Albert i 1983). 
Most recent preliminary data have reported on 
identical blood glucose nadirs after injection o f 
0.15 U/kg BHPI and BHI (Wright, Hampton, Stout, 
Morgan and Marks 1985) as well as on a smaller 
blood glucose decrease following administration of 
0.1 U/kg BHPI (Williams, Berelowitz and Froh-
man 1985). The distinct interindividual variation 
o f the dosage required for the induction of feed­
back-controlled hypoglycemia (Table 1) confirms 
the assumption that the degree o f blood glucose 
decrease achieved by bolus injection of insulin or 
proinsulin is a rather insensitive indicator of biologi­
cal potency and underlines the importance o f feed­
back-controlled hormone infusion according to the 
individual sensitivity by means of a GCIIS. 
In comparison to BHI , BHPI infusion resulted in 
delayed blood glucose decrease reaching a compar­
able nadir, prolonged hypoglycemia and retarded 
recovery. Certainly, this is due to differences in 
the pharmacokinetics o f both hormones including 
different factors such as a higher distribution vol­
ume (Bottermann et al. 1985), compartmentaliza-
t ion (Glauber et al. 1986) and a decreased meta­
bolic clearance rate (Revers et al. 1984). The pro­
longed circulating half-life o f human proinsulin, 
perhaps the most important factor (Glauber et al. 
1986), is demonstrated in Figure 2. 
On the other hand, one can speculate that a pre­
ferential disproportion ally long-lasting effect on 
the liver (suppression o f hepatic glucose production) 
relative to the periphery (stimulation o f glucose 
disposal) must play an additional role (Revers et 
al. 1984; Probst, Hartmann, Jungermann and 
Creutzfeldt 1985; Hartmann, Kramer and Creutz­
feldt 1985). 
Counterregulatory responses o f A C T H , Cortisol, 
G H and prolactin were markedly delayed and pro­
longed after BHPI infusion. Maximum hormone 
responses after either BHPI or B H I were clearly re­
lated i n time to blood glucose nadirs; the greater 
A U C for A C T H , Cortisol and GH corresponded well 
w i t h prolonged hypoglycemia and delayed blood 
glucose recovery. 
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Our results indicate that the course o f time of hor-
monal counterregulation depends on the rate of 
glucose decline during hypoglycemia and that the 
degree of counterregulatory hormone secretion is 
determined not only by the absolute glucose con-
centration, the absolute glucose decrement or the 
rate o f glucose decline (Cryer 1981) but also by the 
duration o f induced hypoglycemia. 
A direct specific pituitary action o f proinsulin on 
A C T H and GH secretion could not be detected. With 
the assumption that epinephrine secretion is reflected 
wi th sufficient reliability by urinary epinephrine ex-
cretion during the collection periods, the more dis-
tinct urinary epinephrine excretion after BHPI is 
a result o f the prolonged hypoglycemia, too. 
Studies on the regulation of serum potassium during 
insulin hypoglycemia tests have shown that the ini -
tial potassium decrease is due to an insulin-induced 
cell-influx, whereas the second phase during blood 
glucose recovery is attributed to epinephrine secre-
tion in response to hypoglycemia (Petersen, Schlü-
ter and Kerp 1982; Brown, M.J., Brown, D.C., and 
Murphy 1983). Therefore, prolonged hypoglycemia 
and increased epinephrine secretion following BHPI 
must result in prolonged and more distinct hypo-
kalemia as well as in delayed serum potassium re-
covery (Fig. 5). 
Intracellular ncuroglucopenia is an effective stimulus 
for prolactin secretion (Woolf, Lee, Leebaw, Thomp-
son, Lilalivathana, Brodows and Campbell 1977), a 
direct blood glucose-independent insulin effect on 
prolactin secretion has not been proven. The pro-
lactin response is not mediated by catecholamines 
(Woolf et al. 1977) and — in comparison wi th other 
conterregulatory hormones — is characterized by a 
physiological interindividual variation which can be 
demonstrated in Table 3. 
Thus, in studies w i t h an only l imited number o f sub-
jects, differences due to the large standard deviation 
may be misinterpreted, hypothesizing e.g. a different 
"hypothalamic handling" o f homologous and hetero-
logous insulins (Rosak, Al thof f , Enzmann and Schöff-
ling 1982). Our data do not support a specific pro-
insulin effect on the hypothalamic-pituitary axis, 
which could have been postulated because of the 
partial structural homology wi th IGF I (Rinderknecht 
andHumbel 1978). 
The delayed and prolonged lactate increase is a con-
sequence of a more distinct epinephrine-induced 
lactate production in muscle (Rosak, Vogel, A l thof f , 
Neubauer, Brecht and Schöffling 1982). 
Proinsulin induced suppression of lipolysis w i t h its 
delayed onset was clearly less pronounced in compari-
son to insulin. With regard to the known sensitivity 
o f the antilipolytic action o f insulin (Zierler and 
Rabinowitz 1964) this finding is rather unexpected 
and points to further differences in metabolic actions 
o f proinsulin and insulin in different organs. 
Reversible heart rate increase and shortening o f the 
systolic time intervals during hypoglycemia were 
identical for BHPI and B H I . They reflect an increase 
in myocardial contractil i ty as a result o f 1. counter-
regulatory epinephrine secretion and 2. a direct ino-
tropic proinsulin or insulin effect (Lee and Downing 
1976; Page, Smith and Watkins 1976; Hilseted, 
Bondes-Petersen, Norgaard, Greniman, Christensen, 
Parvingand Suzuki 1984). 
In conclusion, biosynthetic human proinsulin, when 
infused during GCIIS-guided hypoglycemia test, 
results in delayed and prolonged hypoglycemia with 
consecutively more distinct hormonal counterregula-
tion in comparison to human insulin. We regard this 
as a consequence o f a prolonged circulating and bio-
logical half-life. In addition, a preferential effect on 
the liver (prolonged suppression o f hepatic glucose 
production) may be o f importance. A specific blood 
glucose independent action o f human proinsulin on 
the hypothalamic-pituitary axis cannot be demon-
strated. Whether this "depot effect" may be beneficial 
in the treatment of diabetes mellitus remains to be 
established. 
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